ArticleObstetrics & gynecology science2026
Sexual dysfunction and anxiety disorders among women surviving gynecologic malignancies: a cross-sectional study.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveGynecologic cancer survivors frequently experience sexual dysfunction and anxiety, which can adversely affect their quality of life. Despite its clinical importance, female sexual dysfunction (FSD) remains underrecognized and undertreated. This study aimed to assess the prevalence of FSD and anxiety, as well as their associated factors, among Thai gynecologic cancer survivors.
methodsThis prospective, cross-sectional study was conducted at a university hospital between July 2024 and May 2025. Eligible women aged ≥18 years who had completed treatment for gynecologic cancer at least 6 months prior were recruited. Sexual function was evaluated using the validated female sexual function index (FSFI), with a cutoff ≤26.55 indicating FSD. Anxiety was assessed using the generalized anxiety disorder seven-item scale. Associations with FSD were analyzed using the chi-square test and logistic regression analysis.
resultsOf the 202 eligible women, 160 (79.0%) participated in the study. Most participants were postmenopausal (84.38%) and had an early stage disease (78.12%). The prevalence of FSD was 84.38%, with the lowest FSFI domain scores observed for arousal, lubrication, orgasm, and pain. Anxiety was predominantly mild (77.78%), with only one participant reporting severe symptoms. Multivariable analysis identified age ≥50 years (adjusted odds ratio [OR], 9.84; P<0.001) and alcohol consumption (adjusted OR, 0.25; P=0.033) as independent factors associated with FSD.
conclusionFSD is highly prevalent among Thai gynecologic cancer survivors; however, anxiety is generally mild. Routine assessment of sexual health and multidisciplinary management should be considered a part of survivorship care to improve overall well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.